Prebiotics, Gut Microbiota, and Cardiometabolic Health
The Effect of Prebiotics on Insulin Sensitivity, Metabolic Flexibility, and Cardiovascular Health in Prediabetic Adults.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Blacksburg, Virginia, United States, 24061
- Virginia Polytechnic and State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women; postmenopausal women not taking hormone replacement therapy.
- Fasting glucose between 5.6 - 6.9 mmol/L and/or a 2h plasma glucose between 7.8-11.1 mmol/L following a 75 g oral glucose tolerance test.
- Weight stable for previous 6 months (+/- 2.0 kg).
- Sedentary to recreationally active
- Willing to be randomized to treatment or placebo.
- Verbal and written informed consent.
- No plans to gain/lose weight or change physical activity level.
- Willing to pick up food daily, and consume foods provided for the 6-week controlled feeding period.
Exclusion Criteria:
- BMI less than 25 kg/m2 or greater than 40 kg/m2 or body mass greater than 300 pounds due to limit of DEXA.
- Diabetes or diabetes medications
- Prebiotic or probiotic supplement or product consumption in prior 3 months.
- Total cholesterol > 6.2 mmol/L; triglycerides > 4.5 mmol/L.
- Blood pressure > 140/90 mmHg or antihypertensive medications.
- Diagnosed inflammatory disease (e.g. lupus, irritable bowel, periodontal disease, etc)
- Fructo, galacto-, xylo-oligosaccharide intake > 3 g/day.
- Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease.
- Smoking, alcohol consumption > 2 servings /d for males and 1 serving/d for females, or taking medications (including but not limited to statins or other drugs with anti-inflammatory actions) or antioxidant vitamins or supplements.
- Known allergy, hypersensitivity, or intolerance to inulin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inulin
Participants will receive 10 g of inulin powder each day for 6 weeks.
|
The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Other Names:
|
|
Placebo Comparator: Placebo
Participants will receive 10 g of maltodextrin each day for 6 weeks.
|
The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in insulin sensitivity.
Time Frame: Baseline, 6 weeks
|
Insulin sensitivity will be assessed via a frequently sampled intravenous glucose tolerance test.
|
Baseline, 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in metabolic flexibility.
Time Frame: Baseline, 6 weeks
|
Metabolic flexibility will be measured in skeletal muscle biopsies prior to and 4 hours following a high fat meal.
|
Baseline, 6 weeks
|
|
Change in endothelial function.
Time Frame: Baseline, 6 weeks
|
Flow mediated dilation of the brachial artery will be assessed using duplex ultrasonography with a high resolution linear array transducer according to published guidelines.
|
Baseline, 6 weeks
|
|
Change in arterial stiffness.
Time Frame: Baseline, 6 weeks
|
Arterial stiffness will be measured via carotid femoral pulse wave velocity.
|
Baseline, 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kevin P Davy, PhD, Virginia Polytechnic and State University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Metabolic Diseases
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Nutritional and Metabolic Diseases
- Prediabetic State
- Dietary Supplements
- Food
- Diet, Food, and Nutrition
- Physiological Phenomena
- Food and Beverages
- Dietary Carbohydrates
- Carbohydrates
- Polymers
- Macromolecular Substances
- Polysaccharides
- Starch
- Glucans
- Biopolymers
- Fructans
- Dietary Fiber
- Polysaccharides, Bacterial
- Inulin
- Prebiotics
Other Study ID Numbers
Other Study ID Numbers
- Prebiotics-Prediabetes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.